JP2015517563A - Ｋｖ３阻害剤としてのヒダントイン誘導体 - Google Patents
Ｋｖ３阻害剤としてのヒダントイン誘導体 Download PDFInfo
- Publication number
- JP2015517563A JP2015517563A JP2015513268A JP2015513268A JP2015517563A JP 2015517563 A JP2015517563 A JP 2015517563A JP 2015513268 A JP2015513268 A JP 2015513268A JP 2015513268 A JP2015513268 A JP 2015513268A JP 2015517563 A JP2015517563 A JP 2015517563A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- halo
- oxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1(*)OC(C)=C(C)O1 Chemical compound CC1(*)OC(C)=C(C)O1 0.000 description 2
- MWXJLTQABGVNHS-UHFFFAOYSA-N CC1=C(C)COC1 Chemical compound CC1=C(C)COC1 MWXJLTQABGVNHS-UHFFFAOYSA-N 0.000 description 1
- MHUAPBWYULPSFV-UHFFFAOYSA-N CC1=C(C)N=COC1 Chemical compound CC1=C(C)N=COC1 MHUAPBWYULPSFV-UHFFFAOYSA-N 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N COc1ccccc1 Chemical compound COc1ccccc1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1209013.0 | 2012-05-22 | ||
| GBGB1209013.0A GB201209013D0 (en) | 2012-05-22 | 2012-05-22 | Novel compounds |
| GBGB1209986.7A GB201209986D0 (en) | 2012-06-06 | 2012-06-06 | Novel compounds |
| GB1209986.7 | 2012-06-06 | ||
| GBGB1222528.0A GB201222528D0 (en) | 2012-12-13 | 2012-12-13 | Novel uses |
| GB1222528.0 | 2012-12-13 | ||
| PCT/GB2013/051343 WO2013175211A1 (en) | 2012-05-22 | 2013-05-22 | Hydantoin derivatives as kv3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517563A true JP2015517563A (ja) | 2015-06-22 |
| JP2015517563A5 JP2015517563A5 (enExample) | 2016-07-07 |
Family
ID=48534442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513268A Pending JP2015517563A (ja) | 2012-05-22 | 2013-05-22 | Ｋｖ３阻害剤としてのヒダントイン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9669030B2 (enExample) |
| EP (1) | EP2852588B8 (enExample) |
| JP (1) | JP2015517563A (enExample) |
| CN (1) | CN104334548A (enExample) |
| BR (1) | BR112014028718A2 (enExample) |
| IN (1) | IN2014KN02409A (enExample) |
| WO (1) | WO2013175211A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019502696A (ja) * | 2015-12-16 | 2019-01-31 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３チャネルのヒダントインモジュレーター |
| JP2022502370A (ja) * | 2018-09-21 | 2022-01-11 | バイオノミクス リミテッド | 置換ピリジニル化合物およびその使用 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2509961B1 (en) | 2009-12-11 | 2016-03-09 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| JP2015517563A (ja) | 2012-05-22 | 2015-06-22 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤としてのヒダントイン誘導体 |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| PL3867247T3 (pl) * | 2018-10-16 | 2024-12-09 | Autifony Therapeutics Limited | Nowe związki |
| AU2019296526B2 (en) * | 2019-03-25 | 2026-02-19 | Bionomics Limited | Substituted-N-heteroaryl compounds and uses thereof |
| BR112022013339A2 (pt) | 2020-02-06 | 2022-09-13 | Autifony Therapeutics Ltd | Moduladores de kv3 |
| CA3226856A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011069951A1 (en) * | 2009-12-11 | 2011-06-16 | Glaxo Group Limited | Imidazolidinedione derivatives |
| JP2014516073A (ja) * | 2011-06-07 | 2014-07-07 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤としてのヒダントイン誘導体 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3015090A1 (de) | 1980-04-19 | 1981-10-22 | Basf Ag, 6700 Ludwigshafen | ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen |
| DE3133405A1 (de) | 1981-08-24 | 1983-03-10 | Basf Ag, 6700 Ludwigshafen | 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide |
| US4675403A (en) | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| JP2514945B2 (ja) | 1987-02-05 | 1996-07-10 | 三井石油化学工業株式会社 | 芳香族アミン誘導体 |
| DE3810848A1 (de) | 1988-03-30 | 1989-10-19 | Boehringer Ingelheim Kg | Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung |
| DE3836175A1 (de) | 1988-10-24 | 1990-05-03 | Bayer Ag | Fluor enthaltende phenole |
| WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
| US5362878A (en) | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| US6002016A (en) | 1991-12-20 | 1999-12-14 | Rhone-Poulenc Agrochimie | Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones |
| DK123493D0 (da) | 1993-11-01 | 1993-11-01 | Lundbeck & Co As H | Compounds |
| MX9708802A (es) | 1995-05-17 | 1998-02-28 | Du Pont | Amidas ciclicas fungicidas. |
| WO1996036229A1 (en) | 1995-05-17 | 1996-11-21 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
| PL324291A1 (en) | 1995-06-20 | 1998-05-11 | Du Pont | Anthropodicidal and fungicidal cyclic amides |
| AU3889097A (en) | 1996-08-01 | 1998-02-25 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| CZ184599A3 (cs) | 1996-11-26 | 1999-09-15 | E. I. Du Pont De Nemours And Company | Methylem substituované fungicidy a artropodicidy |
| AU6040398A (en) | 1997-01-30 | 1998-08-25 | E.I. Du Pont De Nemours And Company | Fungicidal compositions |
| JP4171549B2 (ja) | 1998-01-28 | 2008-10-22 | 大正製薬株式会社 | 含フッ素アミノ酸誘導体 |
| JP2000072731A (ja) | 1998-08-31 | 2000-03-07 | Taisho Pharmaceut Co Ltd | ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物 |
| JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | ６−フルオロビシクロ［３．１．０］ヘキサン誘導体 |
| BR0012697A (pt) | 1999-07-23 | 2002-04-09 | Shionogi & Co | Inibidores da diferenciação de th2 |
| US20030149061A1 (en) | 2000-04-04 | 2003-08-07 | Yoshitaka Nishihara | Oily compositions containing highly fat-soluble drugs |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| JPWO2003048134A1 (ja) | 2001-12-05 | 2005-04-14 | 日本たばこ産業株式会社 | トリアゾール化合物及びその医薬用途 |
| AU2003210916B9 (en) | 2002-02-07 | 2008-12-18 | The Curators Of The University Of Missouri | Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds |
| US20050009817A1 (en) | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| GB0325175D0 (en) | 2003-10-28 | 2003-12-03 | Novartis Ag | Organic compounds |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| HUP0401523A3 (en) * | 2004-07-29 | 2007-05-02 | Richter Gedeon Vegyeszet | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
| US20060211697A1 (en) | 2004-12-08 | 2006-09-21 | Liren Huang | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| BRPI0709771B1 (pt) | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| WO2008140895A1 (en) | 2007-04-20 | 2008-11-20 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| EP2242747A1 (de) | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| KR20110094352A (ko) | 2008-12-22 | 2011-08-23 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| TW201144298A (en) | 2009-12-14 | 2011-12-16 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| KR101862375B1 (ko) * | 2010-12-06 | 2018-05-29 | 오티포니 세라피틱스 리미티드 | Kv3 억제제로서 유용한 하이단토인 유도체 |
| FR2968721B1 (fr) * | 2010-12-09 | 2015-07-24 | Valeo Equip Electr Moteur | Circuit de demarreur pour vehicule automobile comportant un dispositif de rehaussement de tension de batterie et demarreur equipe |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| PL2788339T3 (pl) | 2011-12-06 | 2016-09-30 | Pochodne hydantoiny przydatne jako inhibitory KV3 | |
| JP2015517563A (ja) | 2012-05-22 | 2015-06-22 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤としてのヒダントイン誘導体 |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
-
2013
- 2013-05-22 JP JP2015513268A patent/JP2015517563A/ja active Pending
- 2013-05-22 EP EP13725443.9A patent/EP2852588B8/en active Active
- 2013-05-22 WO PCT/GB2013/051343 patent/WO2013175211A1/en not_active Ceased
- 2013-05-22 BR BR112014028718A patent/BR112014028718A2/pt not_active IP Right Cessation
- 2013-05-22 CN CN201380026712.4A patent/CN104334548A/zh active Pending
- 2013-05-22 US US14/403,011 patent/US9669030B2/en not_active Expired - Fee Related
-
2014
- 2014-10-29 IN IN2409KON2014 patent/IN2014KN02409A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011069951A1 (en) * | 2009-12-11 | 2011-06-16 | Glaxo Group Limited | Imidazolidinedione derivatives |
| JP2013513564A (ja) * | 2009-12-11 | 2013-04-22 | アウトイフオンイ トヘラペウトイクス リミテッド | イミダゾリジンジオン誘導体 |
| JP2014516073A (ja) * | 2011-06-07 | 2014-07-07 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤としてのヒダントイン誘導体 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019502696A (ja) * | 2015-12-16 | 2019-01-31 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３チャネルのヒダントインモジュレーター |
| JP7036725B2 (ja) | 2015-12-16 | 2022-03-15 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３チャネルのヒダントインモジュレーター |
| JP2022502370A (ja) * | 2018-09-21 | 2022-01-11 | バイオノミクス リミテッド | 置換ピリジニル化合物およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2852588A1 (en) | 2015-04-01 |
| US9669030B2 (en) | 2017-06-06 |
| US20150157631A1 (en) | 2015-06-11 |
| WO2013175211A1 (en) | 2013-11-28 |
| BR112014028718A2 (pt) | 2017-06-27 |
| EP2852588B8 (en) | 2018-01-10 |
| EP2852588B1 (en) | 2017-11-29 |
| IN2014KN02409A (enExample) | 2015-05-01 |
| CN104334548A (zh) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9669030B2 (en) | Hydantoin derivatives as Kv3 inhibitors | |
| US11180461B2 (en) | Triazoles as Kv3 inhibitors | |
| WO2013182851A1 (en) | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required | |
| JP6118927B2 (ja) | Ｋｖ３阻害剤として有用なヒダントイン誘導体 | |
| CN103596943B (zh) | 用作kv3抑制剂的乙内酰脲衍生物 | |
| JP2025003958A (ja) | 疼痛を治療するためのｋｖ３チャネルのモジュレーター | |
| EP3390394B1 (en) | Hydantoin modulators of kv3 channels | |
| BR112014013400B1 (pt) | Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180417 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181204 |